Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

IPC is delighted to welcome Dermavant as a new 2021 corporate member. Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company committed to fostering unprecedented change and unparalleled impact in immuno-dermatology. They do this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases. Dermavant’s senior leadership team consists of accomplished biopharmaceutical executives in medical dermatology. Members of the team have a proven track record of developing and commercializing innovative products that are among the best-known prescription dermatology brands. They possess rich industry knowledge, a passion for science, and a shared commitment to improving patients’ lives. The US-based company has robust medical dermatology pipeline includes both late-stage and early-development product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets, psoriasis and atopic dermatitis. Dermavant recently issued a press release on the Tapinarof long-term study.

As a network of the leading experts in psoriasis, IPC convenes, collaborates and partners with all stakeholders in order to exchange knowledge and influence how patients are treated around the world. Corporate partners provide unrestricted funds which support the work and mission of the organization.

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.